Incidence of intermediate syndrome in organophosphorous poisoning.
Seventy two patients admitted to the Intensive Care Unit following ingestion of organophosphorus compounds were studied prospectively with two different doses of pralidoxime (PAM). One group received 1 gm immediately after admission and no further PAM and the other group received infusion of PAM, 1 gm 8 hourly for four days (total 12 gms). The incidence of type II paralysis or intermediate syndrome was 47%. We observed a higher incidence in the 4 days of infusion of PAM group (61%) (20 patients) as compared to the single Bolus dose group (39%) (13 patients). Relative risk 1.48 (confidence interval = 0.9-2.4).
Samuel
J
J
Department of Medicine, Christian Medical College & Hospital, Tamil Nadu.
Thomas
K
K
Jeyaseelan
L
L
Peter
J V
JV
Cherian
A M
AM
D000328:Adult; D002801:Cholinesterase Reactivators / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D062787:Drug Overdose / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D062025:Organophosphate Poisoning; D010243:Paralysis / Q000139:chemically induced* / Q000188:drug therapy; D011220:Pralidoxime Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D012133:Respiratory Paralysis / Q000139:chemically induced* / Q000188:drug therapy; D013577:Syndrome
D002801:Cholinesterase Reactivators; D011220:Pralidoxime Compounds; C028797:pralidoxime